Diagnostic Accuracy of HLA-B*57:01 Screening for The Prediction of Abacavir Hypersensitivity and Clinical Utility of the Test: A Meta-Analytic Review

References

• Foster RH , FauldsD . Abacavir . Drugs55 ( 5 ), 729 – 736 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Hervey PS , PerryM . Abacavir: a review of its clinical potential in patients with HIV infection.Drugs60 ( 2 ), 447 – 479 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Chaponda M , PirmohamedM . Hypersensitivity reactions to HIV therapy . Br. J. Clin. Pharmacol.71 ( 5 ), 659 – 671 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hetherington S , McGuirkS , PowellGet al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir . Clin. Ther.23 ( 10 ), 1603 – 1614 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Clay PG . The abacavir hypersensitivity reaction: a review . Clin. Ther.24 ( 10 ), 1502 – 1514 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Chung WH , HungSI , ChenYT . Human leukocyte antigens and drug hypersensitivity.Curr. Opin. Allergy Clin. Immunol.7 ( 4 ), 317 – 323 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Phillips EJ , MallalSA . Pharmacogenetics of drug hypersensitivity.Pharmacogenomics11 ( 7 ), 973 – 987 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Pavlos R , MallalS , PhillipsE . HLA and pharmacogenetics of drug hypersensitivity . Pharmacogenomics13 ( 11 ), 1285 – 1306 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Mallal S , NolanD , WittCet al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir . Lancet359 ( 9308 ), 727 – 732 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Hetherington S , HughesAR , MostellerMet al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir . Lancet359 ( 9312 ), 1121 – 1122 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Martin AM , NolanD , GaudieriSet al. Predisposition to abacavir hypersensitivity conferred by HLA-B*57:01 and a haplotypic Hsp70-Hom variant . Proc. Natl Acad. Sci. USA101 ( 12 ), 4180 – 4185 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Rauch A , NolanD , MartinA , McKinnonE , AlmeidaC , MallalS . Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study . Clin. Infect. Dis.43 ( 1 ), 99 – 102 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Saag M , BaluR , PhillipsEet al. Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46 ( 7 ), 1111 – 1118 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Mallal S , PhillipsE , CarosiGet al. PREDICT-1 Study Team. HLA-B*57:01 screening for hypersensitivity to abacavir . N. Engl. J. Med.358 ( 6 ), 568 – 579 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gatsonis C , PaliwalP . Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer.AJR Am. J. Roentgenol.187 ( 2 ), 271 – 281 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Whiting PF , RutjesAW , WestwoodMEet al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155 ( 8 ), 529 – 536 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) tool. www.bris.ac.uk/quadas
   Google Scholar
• Hughes AR , MostellerM , BansalATet al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5 ( 2 ), 203 – 211 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Bowonwatanuwong C , WarrenL , MostellerMet al. Association of HLA–B*5701 and hypersensitivity to abacavir in a sample of Thai patients . Presented at: 7th International Workshop on Adverse Drug Reactions and Lipodystrophyin HIV . Dublin, Ireland , 13 – 16November 2005 .
   Google Scholar
• Reeves I , ChurchillD , FisherM . Screening for HLA-B*5701 reduces the frequency of abacavir hypersenitivity reactions . Presented at: 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV . CA, USA , 24 – 26September 2006 .
   Google Scholar
• Stekler J , MaenzaJ , StevensCet al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 20 ( 9 ), 1269 – 1274 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Rodríguez-Nóvoa S , García-GascóP , BlancoFet al. Value of the HLA-B*57:01 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res. Hum. Retroviruses 23 ( 11 ), 1374 – 1376 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Phillips E , RauchA , NolanDet al. Genetic characterization of patients with MHC class I mediated abacavir hypersensitivity reaction . Presented at: 4th International AIDS Society meeting . Sydney, Australia , 23 – 25July 2007 . 
   Google Scholar
• Waters LJ , MandaliaS , GazzardB , NelsonM . Prospective HLA-B*57:01 screening and abacavir hypersensitivity: a single centre experience . AIDS21 ( 18 ), 2533 – 2534 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Zucman D , TruchisPd , MajerholcC , StegmanS , Caillat-ZucmanS . Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population.J. Acquir. Immune Defic. Syndr.45 ( 1 ), 1 – 3 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Khan F , GillJ , BerkaN . Strong association of HLA-B*57:01 with abacavir hypersensitivity among HIV-1 positive patients: a potential pharmacogenetic predictive test. . Presented at: 34th Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics . Toronto, Canada , 27 – 31October 2008 .
   Google Scholar
• Rauch A , NolanD , ThurnheerCet al. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 13 ( 8 ), 1019 – 1028 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Giorgini S , MartinelliC , TognettiLet al. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Dermatol. Ther. 24 ( 6 ), 591 – 594 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Berka N , GillJM , LiaciniA , O’BryanT , KhanFM . Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency virus-positive patients from southern Alberta.Hum. Immunol.73 ( 2 ), 164 – 167 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lijmer JG , BossuytPM , HeisterkampSH . Exploring sources of heterogeneity in systematic reviews of diagnostic tests.Stat. Med.21 ( 11 ), 1525 – 1537 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• DerSimonian R , LairdN . Meta-analysis in clinical trials.Control. Clin. Trials7 ( 3 ), 177 – 188 ( 1986 ).
   PubMedGoogle Scholar
• Higgins JP , ThompsonSG . Quantifying heterogeneity in a meta-analysis.Stat. Med.21 ( 11 ), 1539 – 1558 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Moses LE , ShapiroD , LittenbergB . Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations.Stat. Med.12 ( 14 ), 1293 – 1316 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Zamora J , AbrairaV , MurielA , KhanK , CoomarasamyA . Meta-DiSc: a software for meta-analysis of test accuracy data.BMC Med. Res. Methodol.6 , 31 ( 2006 ).
   PubMedGoogle Scholar
• Meta-DiSc software version 1.4. www.hrc.es/investigacion/metadisc_en.htm
   Google Scholar
• Open Meta-Analyst. http://tuftscaes.org/open_meta
   Google Scholar
• Egger M , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test.BMJ315 ( 7109 ), 629 – 634 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Nieves Calatrava D , Calle-Martín OdeL , Iribarren-LoyarteJAet al. Cost-effectiveness analysis of HLA-B*57:01 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm. Infecc. Microbiol. Clin. 28 ( 9 ), 590 – 595 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Kauf TL , FarkouhRA , EarnshawSR , WatsonME , MaroudasP , ChambersMG . Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.Pharmacoeconomics28 ( 11 ), 1025 – 1039 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Somkrua R , EickmanEE , SaokaewS , LohitnavyM , ChaiyakunaprukN . Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.BMC Med. Genet.12 , 118 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Yip VL , MarsonAG , JorgensenAL , PirmohamedM , AlfirevicA . HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.Clin. Pharmacol. Ther.92 ( 6 ), 757 – 765 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cheung YK , ChengSH , ChanEJ , LoSV , NgMH , KwanP . HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.Epilepsia54 ( 7 ), 1307 – 1314 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Tangamornsuksan W , ChaiyakunaprukN , SomkruaR , LohitnavyM , TassaneeyakulW . Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.JAMA Dermatol.149 ( 9 ), 1025 – 1032 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Hughes DA , VilarFJ , WardCC , AlfirevicA , ParkBK , PirmohamedM . Cost–effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity.Pharmacogenetics14 ( 6 ), 335 – 342 ( 2004 ).
   PubMedGoogle Scholar
• Schackman BR , ScottCA , WalenskyRP , LosinaE , FreedbergKA , SaxPE . The cost–effectiveness of HLA-B*57:01 genetic screening to guide initial antiretroviral therapy for HIV.AIDS22 ( 15 ), 2025 – 2033 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Guo Y , ShiL , HongH , SuZ , FuscoeJ , NingB . Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.Sci. China Life Sci.56 ( 2 ), 119 – 124 ( 2013 )
   PubMed Web of Science ®Google Scholar
• Saito S , OtaS , YamadaE , InokoH , OtaM . Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population.Tissue Antigens56 ( 6 ), 522 – 529 ( 2000 ).
   PubMedGoogle Scholar
• Munderi P , SnowdenWB , WalkerASet al. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop. Med. Int. Health 16 ( 2 ), 200 – 204 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Martin MA , KroetzDL . Abacavir pharmacogenetics-from initial reports to standard of care.Pharmacotherapy33 ( 7 ), 765 – 775 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gazzard BG , AndersonJ , BabikerAet al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 9 ( 8 ), 563 – 608 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Aberg JA , KaplanJE , LibmanHet al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49 ( 5 ), 651 – 681 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Antinori A , MarcotullioS , AmmassariAet al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 35 ( 2 ), 113 – 159 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lalonde RG , ThomasR , RachlisAet al. Successful implementation of a national HLA-B*57:01 genetic testing service in Canada. Tissue Antigens 75 ( 1 ), 12 – 18 ( 2010 ).
   PubMedGoogle Scholar